Concepts (170)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Alopecia | 19 | 2020 | 351 | 7.05 | Why? |
| Minoxidil | 8 | 2019 | 28 | 3.50 | Why? |
| Receptors, Androgen | 7 | 2020 | 212 | 3.23 | Why? |
| Androgens | 7 | 2021 | 267 | 2.93 | Why? |
| Hair Follicle | 4 | 2018 | 44 | 2.32 | Why? |
| Sulfotransferases | 4 | 2019 | 25 | 1.88 | Why? |
| Androgen Antagonists | 6 | 2021 | 404 | 1.88 | Why? |
| Vasodilator Agents | 3 | 2018 | 344 | 1.25 | Why? |
| 5-alpha Reductase Inhibitors | 1 | 2020 | 30 | 0.87 | Why? |
| Work Schedule Tolerance | 1 | 2020 | 158 | 0.75 | Why? |
| Maternal Inheritance | 1 | 2017 | 6 | 0.73 | Why? |
| Mitochondrial Proton-Translocating ATPases | 1 | 2017 | 11 | 0.72 | Why? |
| Esthetics | 1 | 2018 | 136 | 0.71 | Why? |
| Encephalitis, Herpes Simplex | 1 | 2017 | 26 | 0.69 | Why? |
| Nipples | 1 | 2017 | 21 | 0.69 | Why? |
| Pigmentation | 1 | 2017 | 21 | 0.68 | Why? |
| Mammary Glands, Human | 1 | 2017 | 23 | 0.68 | Why? |
| Sildenafil Citrate | 1 | 2017 | 66 | 0.67 | Why? |
| Melanins | 1 | 2017 | 42 | 0.65 | Why? |
| Herpes Genitalis | 1 | 2017 | 90 | 0.65 | Why? |
| Prodrugs | 1 | 2018 | 264 | 0.62 | Why? |
| Circadian Rhythm | 1 | 2020 | 607 | 0.54 | Why? |
| Patient Acuity | 1 | 2020 | 1755 | 0.51 | Why? |
| Stem Cells | 1 | 2017 | 595 | 0.45 | Why? |
| Prostatic Neoplasms | 2 | 2020 | 1637 | 0.43 | Why? |
| Mitochondria | 1 | 2017 | 857 | 0.41 | Why? |
| Aspirin | 1 | 2018 | 1043 | 0.41 | Why? |
| Spironolactone | 2 | 2020 | 114 | 0.39 | Why? |
| Genetic Variation | 2 | 2020 | 3919 | 0.38 | Why? |
| Chromosomes, Human, X | 2 | 2020 | 81 | 0.37 | Why? |
| Enzyme Inhibitors | 1 | 2018 | 1881 | 0.35 | Why? |
| Disease Susceptibility | 1 | 2020 | 4002 | 0.33 | Why? |
| Patient Admission | 2 | 2020 | 5250 | 0.32 | Why? |
| Hair | 2 | 2018 | 175 | 0.32 | Why? |
| Life Style | 1 | 2018 | 2708 | 0.30 | Why? |
| Dermatology | 1 | 2020 | 1999 | 0.28 | Why? |
| Administration, Topical | 3 | 2018 | 272 | 0.25 | Why? |
| Virus Internalization | 3 | 2020 | 7921 | 0.24 | Why? |
| Genetic Predisposition to Disease | 1 | 2017 | 4027 | 0.24 | Why? |
| Pneumonia, Viral | 9 | 2020 | 243684 | 0.23 | Why? |
| Oxandrolone | 1 | 2021 | 4 | 0.23 | Why? |
| Thiohydantoins | 1 | 2021 | 5 | 0.23 | Why? |
| Coronavirus Infections | 9 | 2020 | 253789 | 0.23 | Why? |
| Trichuris | 1 | 2020 | 23 | 0.22 | Why? |
| Dutasteride | 1 | 2020 | 22 | 0.22 | Why? |
| Finasteride | 1 | 2020 | 29 | 0.22 | Why? |
| Anabolic Agents | 1 | 2021 | 49 | 0.22 | Why? |
| ARNTL Transcription Factors | 1 | 2020 | 17 | 0.22 | Why? |
| Administration, Cutaneous | 2 | 2018 | 229 | 0.22 | Why? |
| Hyperandrogenism | 1 | 2020 | 36 | 0.22 | Why? |
| Serine | 1 | 2020 | 90 | 0.21 | Why? |
| Oxazoles | 1 | 2021 | 75 | 0.21 | Why? |
| DNA Repair | 1 | 2020 | 114 | 0.21 | Why? |
| Alopecia Areata | 1 | 2021 | 140 | 0.19 | Why? |
| Piloerection | 1 | 2017 | 2 | 0.19 | Why? |
| Synephrine | 1 | 2017 | 2 | 0.19 | Why? |
| Adrenergic alpha-1 Receptor Agonists | 1 | 2017 | 3 | 0.18 | Why? |
| Mineralocorticoid Receptor Antagonists | 1 | 2020 | 203 | 0.18 | Why? |
| Ovulation | 1 | 2017 | 9 | 0.18 | Why? |
| Trinucleotide Repeats | 1 | 2017 | 7 | 0.18 | Why? |
| Genetic Loci | 1 | 2020 | 439 | 0.18 | Why? |
| Polycystic Ovary Syndrome | 1 | 2021 | 151 | 0.18 | Why? |
| Ion Transport | 1 | 2017 | 43 | 0.18 | Why? |
| Fertilization | 1 | 2017 | 49 | 0.18 | Why? |
| Epidemiologic Studies | 1 | 2020 | 554 | 0.17 | Why? |
| Gonadal Steroid Hormones | 1 | 2020 | 328 | 0.17 | Why? |
| Ovarian Follicle | 1 | 2017 | 34 | 0.17 | Why? |
| Acne Vulgaris | 1 | 2021 | 198 | 0.17 | Why? |
| Cultural Characteristics | 1 | 2018 | 159 | 0.17 | Why? |
| Male | 20 | 2021 | 367725 | 0.17 | Why? |
| Humans | 35 | 2021 | 930598 | 0.17 | Why? |
| Disease Transmission, Infectious | 1 | 2020 | 9044 | 0.16 | Why? |
| Gene Expression | 2 | 2017 | 3332 | 0.16 | Why? |
| Altitude | 1 | 2020 | 311 | 0.16 | Why? |
| Unnecessary Procedures | 1 | 2018 | 175 | 0.16 | Why? |
| Permeability | 1 | 2017 | 238 | 0.16 | Why? |
| Severity of Illness Index | 4 | 2021 | 48226 | 0.16 | Why? |
| Adult | 17 | 2021 | 244371 | 0.16 | Why? |
| Promoter Regions, Genetic | 1 | 2020 | 823 | 0.15 | Why? |
| Genetic Diseases, X-Linked | 1 | 2018 | 237 | 0.15 | Why? |
| Disease Outbreaks | 2 | 2021 | 27595 | 0.14 | Why? |
| Population Density | 1 | 2020 | 694 | 0.14 | Why? |
| Betacoronavirus | 6 | 2020 | 204454 | 0.14 | Why? |
| Pandemics | 10 | 2020 | 389249 | 0.14 | Why? |
| Transcription, Genetic | 1 | 2020 | 1326 | 0.13 | Why? |
| Selection, Genetic | 1 | 2017 | 691 | 0.13 | Why? |
| Adaptation, Physiological | 1 | 2017 | 359 | 0.13 | Why? |
| Middle Aged | 11 | 2020 | 270681 | 0.13 | Why? |
| Melatonin | 1 | 2020 | 578 | 0.13 | Why? |
| Blood-Brain Barrier | 1 | 2017 | 531 | 0.12 | Why? |
| Observational Studies as Topic | 1 | 2020 | 1887 | 0.12 | Why? |
| Sex Factors | 2 | 2020 | 11014 | 0.12 | Why? |
| Calcium | 1 | 2017 | 708 | 0.12 | Why? |
| Serine Endopeptidases | 4 | 2020 | 4606 | 0.12 | Why? |
| Sequence Analysis, DNA | 1 | 2020 | 2830 | 0.11 | Why? |
| Spain | 2 | 2020 | 15545 | 0.11 | Why? |
| Cell Differentiation | 1 | 2017 | 1338 | 0.11 | Why? |
| Drug Interactions | 1 | 2018 | 1653 | 0.11 | Why? |
| Young Adult | 7 | 2020 | 93724 | 0.10 | Why? |
| Spike Glycoprotein, Coronavirus | 2 | 2020 | 37182 | 0.10 | Why? |
| Age Distribution | 1 | 2020 | 3567 | 0.10 | Why? |
| Up-Regulation | 1 | 2017 | 2249 | 0.10 | Why? |
| Prevalence | 3 | 2020 | 25773 | 0.09 | Why? |
| Peptides | 1 | 2020 | 2513 | 0.09 | Why? |
| Risk | 1 | 2020 | 5288 | 0.09 | Why? |
| Female | 14 | 2021 | 380317 | 0.09 | Why? |
| Risk Factors | 4 | 2020 | 71621 | 0.08 | Why? |
| Sleep | 1 | 2020 | 2695 | 0.08 | Why? |
| Ultraviolet Rays | 1 | 2017 | 1272 | 0.08 | Why? |
| Aged | 6 | 2020 | 215776 | 0.08 | Why? |
| Prospective Studies | 3 | 2020 | 43301 | 0.08 | Why? |
| Symptom Assessment | 1 | 2020 | 4967 | 0.08 | Why? |
| Breast Feeding | 1 | 2017 | 1585 | 0.08 | Why? |
| Risk Assessment | 2 | 2020 | 25439 | 0.07 | Why? |
| Longitudinal Studies | 1 | 2020 | 9893 | 0.07 | Why? |
| Renin-Angiotensin System | 1 | 2020 | 3661 | 0.07 | Why? |
| Intensive Care Units | 2 | 2020 | 29594 | 0.07 | Why? |
| T-Lymphocytes | 1 | 2020 | 6670 | 0.06 | Why? |
| Travel | 1 | 2021 | 7220 | 0.06 | Why? |
| Peptidyl-Dipeptidase A | 2 | 2020 | 9659 | 0.06 | Why? |
| Hirsutism | 1 | 2021 | 15 | 0.06 | Why? |
| Performance-Enhancing Substances | 1 | 2021 | 20 | 0.06 | Why? |
| Photoperiod | 1 | 2020 | 41 | 0.05 | Why? |
| Enzyme Induction | 1 | 2020 | 89 | 0.05 | Why? |
| Animals | 2 | 2020 | 78931 | 0.05 | Why? |
| Wind | 1 | 2020 | 144 | 0.05 | Why? |
| Aged, 80 and over | 2 | 2020 | 88759 | 0.05 | Why? |
| Socioeconomic Factors | 1 | 2017 | 8495 | 0.05 | Why? |
| Biomarkers | 2 | 2020 | 23361 | 0.05 | Why? |
| Viral Load | 1 | 2020 | 15850 | 0.05 | Why? |
| Airports | 1 | 2021 | 284 | 0.05 | Why? |
| Hair Removal | 1 | 2017 | 10 | 0.05 | Why? |
| Cytokines | 1 | 2020 | 15010 | 0.04 | Why? |
| Incidence | 1 | 2020 | 25622 | 0.04 | Why? |
| Treatment Outcome | 3 | 2018 | 51732 | 0.04 | Why? |
| Cardiotonic Agents | 1 | 2020 | 418 | 0.04 | Why? |
| Scalp | 1 | 2017 | 82 | 0.04 | Why? |
| Age Factors | 1 | 2017 | 21039 | 0.04 | Why? |
| Electrocardiography, Ambulatory | 1 | 2017 | 204 | 0.04 | Why? |
| Comorbidity | 1 | 2020 | 34796 | 0.04 | Why? |
| Public Health | 1 | 2020 | 16359 | 0.03 | Why? |
| Drug Resistance | 1 | 2016 | 395 | 0.03 | Why? |
| Infant | 1 | 2017 | 30274 | 0.03 | Why? |
| Adolescent | 3 | 2018 | 86841 | 0.03 | Why? |
| Sex Distribution | 1 | 2020 | 2083 | 0.03 | Why? |
| Patient Reported Outcome Measures | 1 | 2018 | 912 | 0.03 | Why? |
| Treatment Failure | 1 | 2018 | 2106 | 0.03 | Why? |
| China | 1 | 2018 | 50654 | 0.03 | Why? |
| Drug Administration Schedule | 1 | 2018 | 2324 | 0.03 | Why? |
| Biopsy | 1 | 2018 | 2811 | 0.02 | Why? |
| Retrospective Studies | 1 | 2020 | 105322 | 0.02 | Why? |
| Heart Rate | 1 | 2017 | 1527 | 0.02 | Why? |
| Cities | 1 | 2020 | 4937 | 0.02 | Why? |
| Prognosis | 2 | 2021 | 32490 | 0.02 | Why? |
| Dose-Response Relationship, Drug | 1 | 2016 | 3776 | 0.02 | Why? |
| Blood Pressure | 1 | 2017 | 2198 | 0.02 | Why? |
| Time Factors | 2 | 2021 | 31397 | 0.02 | Why? |
| Kidney | 1 | 2020 | 3648 | 0.02 | Why? |
| Receptors, Virus | 1 | 2020 | 5659 | 0.02 | Why? |
| Interleukin-6 | 1 | 2021 | 7522 | 0.02 | Why? |
| Brazil | 1 | 2020 | 12582 | 0.02 | Why? |
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2020 | 5277 | 0.01 | Why? |
| Cross-Sectional Studies | 2 | 2020 | 53120 | 0.01 | Why? |
| Disease Progression | 1 | 2021 | 13580 | 0.01 | Why? |
| Case-Control Studies | 1 | 2020 | 17671 | 0.01 | Why? |
| Models, Theoretical | 1 | 2020 | 6659 | 0.01 | Why? |
| India | 1 | 2018 | 11875 | 0.01 | Why? |
| Obesity | 1 | 2020 | 7388 | 0.01 | Why? |
| Hypertension | 1 | 2020 | 8895 | 0.01 | Why? |
| Global Health | 1 | 2021 | 13911 | 0.01 | Why? |
Goren's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts
(170)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(97)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_